FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 353:1877-1881 November 3, 2005 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Sometime within the next two years, clinical researchers are expected to begin inoculating at least 2000 African infants in the largest trial ever undertaken of an experimental vaccine for malaria. The planned efficacy trial will mark a milestone in the multidecade effort to make a vaccine against one of the world's greatest killers of children. It also represents a high-stakes gamble for the company hoping to license the product, GlaxoSmithKline Biologicals, as well as for funding agencies and the international research community. If the vaccine — known as RTS,S — is found to reduce significantly the rates of death and . . . [Full Text of this Article]

Source Information

Dr. Okie is a contributing editor of the Journal.

This article has been cited by other articles:

• Jarrett, S. W. (2008). Challenges to the Successful Introduction of Biotechnologies in Developing Countries. Public Health Ethics 1: 104-109 [Full Text]  
• Pawluczkowycz, A. W., Lindorfer, M. A., Waitumbi, J. N., Taylor, R. P. (2007). Hematin Promotes Complement Alternative Pathway-Mediated Deposition of C3 Activation Fragments on Human Erythrocytes: Potential Implications for the Pathogenesis of Anemia in Malaria. J. Immunol. 179: 5543-5552 [Abstract] [Full Text]